Evidence map›Paper›PMID 41164195›Full record

ArticleFrontiers in immunology2025

Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning.

Weiran Zhang, Lin Tan, Qiuqiao Mu, Han Zhang, Daqiang Sun

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Aging and lung diseases: Unraveling mechanisms and therapeutic targets.Chinese medical journal pulmonary and critical care medicine · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Weiran Zhang *Tianjin Chest Hospital, Tianjin University, Tianjin, China.
Lin Tan *Qingdao Hospital, University of Health and Rehabilitation Sciences (Qingdao Municipal Hospital), Qingdao, China.
Qiuqiao Mu *Tianjin Chest Hospital, Tianjin University, Tianjin, China.
Han Zhang *Tianjin Chest Hospital, Tianjin University, Tianjin, China.
Daqiang SunTianjin Chest Hospital, Tianjin University, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung adenocarcinoma (LUAD) is the most common subtype of non-small cell lung cancer, with EGFR mutations serving as key oncogenic drivers. However, patients harboring EGFR mutations exhibit considerable heterogeneity in clinical outcomes and treatment responses. Characterizing the malignant features of EGFR-mutant epithelial cells may facilitate improved stratification and personalized therapeutic strategies. Methods: Using publicly available single-cell RNA sequencing data, malignant epithelial cells were identified in EGFR-mutant LUAD samples via inferCNV and k-means clustering. Pseudotime trajectories were constructed using Monocle2, and branch-specific genes were extracted for functional analysis. Differentially expressed genes were integrated with TCGA bulk transcriptomic data, and ten machine learning algorithms were applied to construct the EGFR Mutation-Associated Malignant Epithelial Cell-Related Signature (EGFRmERS). The prognostic value of EGFRmERS was validated across multiple independent cohorts. Associations between EGFRmERS and immune infiltration, immunotherapy response, tumor mutation burden (TMB), and copy number variations (CNVs) were systematically assessed. The performance of EGFRmERS was also benchmarked against previously published LUAD prognostic signatures. Finally, the core gene PERP was selected for Results: EGFR-mutant epithelial cells were classified into subclusters with varying malignant potential, enriched in pathways such as cell cycle regulation and DNA repair. The EGFRmERS signature robustly predicted patient prognosis across multiple cohorts and outperformed existing models. High EGFRmERS scores were associated with an immunosuppressive microenvironment, reduced immunotherapy responsiveness (as indicated by TIDE and IPS scores), elevated TMB, and increased genomic instability. PERP was identified as a key gene, highly expressed in LUAD and associated with poor prognosis. Functional assays confirmed its role in promoting cell migration, invasion, and clonogenic capacity. Conclusions: This study delineates key malignant programs in EGFR-mutant epithelial cells at the single-cell level and proposes a robust prognostic scoring system, EGFRmERS, with strong predictive power for survival and immunotherapy benefit. PERP was identified as a potential therapeutic target, offering novel insights for precision stratification and treatment in EGFR-mutant LUAD.

Indexed as

Adenocarcinoma of LungEpithelial CellsLung NeoplasmsMachine LearningMutationTranscriptomeAlgorithmsBiomarkers, TumorErbB ReceptorsGene Expression ProfilingGene Expression Regulation, NeoplasticHumansPrognosisSingle-Cell AnalysisBiomarkers, TumorEGFR protein, humanErbB ReceptorsEGFRimmunotherapyLUADmachine learningPERPscRNA-seq

Identifiers

PMID41164195
PMCPMC12558860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.